5 February 2025 - Ministry of Health, Labour and Welfare to evaluate avacincaptad pegol as potential first and only treatment for patients with geographic atrophy secondary to age-related macular degeneration in Japan.

Astellas today announced the submission of a new drug application to Japan's Ministry of Health, Labour and Welfare for conditional approval of avacincaptad pegol intravitreal solution, a synthetic aptamer that inhibits the complement C5 protein, for the treatment of geographic atrophy secondary to age-related macular degeneration. 

Read Astellas press release